Bone Neoplasm - Ewing Sarcoma
NCT01231906
Clinical Trial Information
Trial Number: NCT01231906 (ClinicalTrials.gov)
Disease Type:
- Bone Neoplasm - Ewing Sarcoma
Trial Title:
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Study ID:
AEWS1031
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01231906-D3 | An erratum (PMID 35839523) correcting some minor typos in the original primary publication of trial AEWS1031 was published on July 15, 2022. The data submitted to the Archive (NCT01231906-D1 and NCT01231906-D2) reflect the information corrected by this erratum |
| NCT01231906-D2 | NCT01231906-D2: There are 2 datasets associated with the PMID 34652968: NCT01231906-D1 through NCT01231906-D2. This dataset, NCT01231906-D2, provides the information on adverse events. There are multiple rows per patient one row per patient and adverse event type (AE description). The contents of this submission reflect the correct data described in the July 15, 2022 erratum (PMID 35839523). |
| NCT01231906-D1 | NCT01231906-D1: There are 2 datasets associated with the PMID 34652968: NCT01231906-D1 through NCT01231906-D2. This dataset, NCT01231906-D1, provides the information for the Tables, Figures, and the CONSORT diagram. There is one row per patient. The contents of this submission reflect the correct data described in the July 15, 2022 erratum (PMID 35839523). |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®